[S]-AR-R 15896AR-A novel anticonvulsant: Acute safety, pharmacokinetic and pharmacodynamic properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 121-132

  Palmer, Gene C ^a   Murray, Robert J ^a   Cramer, Carrie L ^a   Stagnitto, Mary L ^a   Knowles, Marilyn K ^a   Freedman, Lou R ^a   Eismann, Mark S ^a   Mahmood, Nik ^a   Balestra, Mike ^a   Borrelli, Alfonso R ^a   Hudzik, Thomas J ^a   McCarthy, Dennis J ^a  

^a Astra Arcus USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANICEMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT THERAPY; ARTICLE; BINDING SITE; CONVULSION; DRUG ELIMINATION; DRUG SAFETY; EPILEPSY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032933069     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Albers GW, Goldberg MP and Choi DW (1992) Do NMDA antagonists prevent neuronal injury? Yes. Arch Neurol 49:418-419.
2. Applegate CD, Samoriski GM and Ozduman K (19971 Effects of valproate, phenytoin, and MK-801 in a novel model of epileptogenesis. Epilepsia 38:631-636.
3. Black MA, Tremblay R, Mealing G, Ray R, Durkin JP, Whitfield JF, Blosser J and Morely P (1995) N-methyl-D-aspartate- or glutamate-mediated toxicity in cultured rat cortical neurons is antagonized by FPL 15896AR. J Neurochem 65:2170-2177.
4. Black MA, Lanthorn T, Small DL, Mealing GAR, Lam V and Morely P (1996) Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2. Eur J Pharmacol 317:377-381.
5. Bradford HF (1995) Glutamate. GABA and epilepsy. Prog Neurobiol 47:477-511.
6. Braun DE and Freed WJ (1990) Effect of nimodipine and anticonvulsants on kainic acid-induced seizures in mice. Brain Res 533:157-160.
7. Chapman AG, Swan JH, Patel S, Graham JL and Meldrum BS (1990) Cerebroprotective and anticonvulsant action of competitive and non-competitive NMDA antagonists, in Amino Acids: Chemistry, Biology and Medicine (Lubec G and Rosenthal GA eds) pp 219-232, ESCOM Publishers, Amsterdam.
8. Cramer CL, Stagnitto ML, Knowles MA and Palmer GC (1994) Kainic acid and 4-aminopyridine seizure models in mice: Evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci 54:PL271-275.
9. Cregan EF, Peeling J, Corbett D, Buchan AM, Saunders J, Auer RN, Gao M, McCarthy DJ, Eisman MS, Campbell TM, Murray RJ, Stagnitto ML and Palmer GC (1997) ARL 15896AR, a low-affinity uncompetitive NMDA antagonist, is effective in rodent models of global and focal ischemia. J Pharmacol Exp Ther 283:1412-1424.
10. Czuczwar SJ, Frey H-H and Loscher W (1985) Antagonism of N-methyl-D, L-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur J Pharmacol 108:273-280.
11. Finney DJ (1971) Probit Analysis, 3rd ed., Cambridge University Press, London.
12. Garske GE, Palmer GC, Napier JJ, Griffith RC, Freedman LR, Harris EW, Ray R, McCreedy SA, Blosser JC, Woodhead JH, White HS and Swinyard EA (1991) Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat. Epilepsy Res 9:161-174.
13. Grant KA, Colombo G, Grant J and Rogawski MA (1996) Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35:1709-1719.
14. Greene JG, Porter RH and Greenamyre JT (1996) ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: Neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp Neurol 137:66-72.
15. Harris EW (1995) Subtypes of glutamate receptors: Pharmacological classification, in CNS Neurotransmitters and Modulators Glutamate (Stone TW ed) pp 95-125, CRC Press, New York.
16. Hudzik TJ and Palmer GC (1995) Effects of anticonvulsants in a novel operant learning paradigm in rats: Comparison of remacemide hydrochioride and FPL 15896AR to other anticonvulsant agents. Epilepsy Res 21:183-193.
17. Hudzik TJ, Freedman L and Palmer GC (1996) Remacemide hydrochioride and ARL 15896AR lack abuse potential: Additional differences from other uncompetitive NMDA antagonists. Epilepsia 37:544-550.
18. Kupferberg HJ (1989) Antiepileptic drug development program: A cooperative effort of government and industry. Epilepsia 30(Suppl. 1):S51-S56.
19. Loscher W and Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145-181.
20. Macdonald RL and Kelly KM (1995) Antiepileptic drug mechanisms of action. Epilepsia 36(Suppl. 2):S1-S12.
21. McNamara JO, Russell RD, Rigsbee L and Bonhaus DW (1988) Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models. Neuropharmacology 27:563-568.
22. Meldrum B (1992) Excitatory amino acids and neuroprotection, in Advances in Neuroprotection Emerging Strategies in Neuroprotection (Marangos PJ and LaI H eds) pp 106-128, Birkhauser, Boston.
23. Monaghan DT and Larsen H (1997) NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther 280:614-620.
24. Muller WE, Mutschler E and Riederer P (1995) Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry 28:113-124.
25. Olney JW (1978) Neurotoxicity of excitatory amino acids, in Kainic Acid as a Tool in Neurobiology (McGeer EG, Olney JW and McGeer PL eds) pp 37-70, Raven Press, New York.
26. Palmer GC, Murray RJ, Wilson TCM, Eisman MS, Ray RK, Griffith RC, Napier JJ, Fedorchuk M, Stagnitto ML and Garste GE (1992) Biological profile of the metabolites and potential metabolites of the anticonvulsant remaceinide. Epilepsy Res 12:9-20.
27. Palmer GC, Stagnitto ML, Garske GE, Napier JJ, Harris EW, Kaiser FC, Griffith RC, Woodhead JH, White HS, Wolf HH and Swinyard EA (1995) Anticonvulsant efficacy/safety properties of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride. J Pharmacol Exp Ther 273:1023-1031.
28. Palmer GC, Murray RJ and McCarthy DJ (1996) Neuroprotective potential of the low affinity NMDA receptor antagonist, ARL 15896AR, in Ischemic Stroke II- Advances in Understanding and Therapy (Savage LM ed) pp 34-64, IBC Biomedical Library Series, Southborough, MA.
29. Palmer GC and Hutchison JB (1997) Preclinical and clinical aspects of remacemide hydrochioride. Excitatory Amino Acids- Clinical Results with Antagonists (Herrling P ed) pp 109-120, Academic Press, New York.
30. Palmer GC, Borrelli AR, Hudzik TJ and Sparber S (1998) Acute heat stress model of epilepsy in weanling rats: Influence of prototypic anti-seizure compounds. Epilepsy Res. 30:203-217.
31. Racine RJ (1972) Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalography Clin Neurophysiol 32:281-294.
32. Rogawski MA, Yamaguchi S-I, Jones SM, Rice KC, Thurkauf A and Monin JA (1991) Anticonvulsant activity of the low affinity uncompetitive N-methyl-D-aspartate antagonist (z)-5-aminocarbonyl-10.11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI): Comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. J Pharmacol Exp Ther 259:30-37.
33. Rogawski MA (1992) The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs 44:279-292.
34. Stagnitto ML, Palmer GC, Ordy JM, Griffith RC, Napier JJ, Becker CN, Gentile RJ, Garske GE, Frankenheim JM, Woodhead JH, White HS and Swinyard EA (1990) Preclinical profile of revnacemide: A novel anticonvulsant effective against maximal electroshock seizures in mice. Epilepsy Res 7:11-28.
35. Subramaniam S, Donevan SD and Rogawski MA (1996) Block of the N-methyl-D-aspartate receptor by remacemide and it des-glycine metabolite. J Pharmacol Exp Ther 276:161-168.
36. Swinyard EA and Woodhead JH (1982) Experimental detection, quantification, and evaluation of anticonvulsants, in Antiepileptic Drugs, 2nd ed (Woodbury DM, Penry JK and Pippenger CE eds) pp 111-126, Raven Prees, New York.
37. Wamil AW and McLean MJ (1993) Effect of temperature on limitation by MK-801 of firing of action potentials by spinal cord neurons in cell culture. Eur J Pharmacol 230:263-269.
38. Willetts J, Balster RL and Leander JD (1990) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428.
39. Yamaguchi S and Rogawski MA (1992) Effects of anticonvulsant drugs on 4-amino-pyridine-induced seizures. Epilepsy Res 11:9-16.
40. Zar JH (1984) Biostastical Analysis, 2nd ed., Prentice-Hall, Englewood Cliffs, New Jersey.